PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Stuart Walter Peltz sold 2,230 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $18.03, for a total transaction of $40,206.90. Following the transaction, the chief executive officer now directly owns 26,646 shares in the company, valued at $480,427.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) traded down $1.80 during trading hours on Tuesday, hitting $21.49. 1,460,000 shares of the company were exchanged, compared to its average volume of 878,114. The company has a quick ratio of 2.97, a current ratio of 3.08 and a debt-to-equity ratio of 0.98. The stock has a market cap of $891.61, a P/E ratio of -7.44 and a beta of 1.23. PTC Therapeutics, Inc. has a 52 week low of $8.12 and a 52 week high of $23.71.
PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.01). PTC Therapeutics had a negative return on equity of 75.19% and a negative net margin of 75.64%. analysts predict that PTC Therapeutics, Inc. will post -2.01 EPS for the current year.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. JPMorgan Chase & Co. lifted their target price on shares of PTC Therapeutics to $15.00 and gave the stock a “neutral” rating in a research report on Friday, November 24th. Bank of America downgraded shares of PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Thursday, October 26th. ValuEngine upgraded shares of PTC Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Cowen restated a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $19.14.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/ptc-therapeutics-inc-ptct-ceo-stuart-walter-peltz-sells-2230-shares/1821383.html.
About PTC Therapeutics
PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.